Evidence and policy for influenza control

Eurosurveillance

Volumn , Issue 27, 2014, Pages

  Kelly, H ^a,b   Cowling, B J ^c  

^a VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

^b The Australian National University   (Australia)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; OSELTAMIVIR; SIALIDASE INHIBITOR;

CLINICAL EFFECTIVENESS; DISEASE CONTROL; DRUG EFFICACY; EDITORIAL; HOSPITAL ADMISSION; HUMAN; INFLUENZA; INFLUENZA A (H1N1); INFLUENZA A (H3N2); INFLUENZA B; INFLUENZA VIRUS A H1N1; META ANALYSIS (TOPIC); MORTALITY; POLYMERASE CHAIN REACTION; CLINICAL FEATURE; COMORBIDITY; DEATH; INFECTION CONTROL; INFECTION RISK; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

EID: 84907712583     PISSN: 1025496X     EISSN: 15607917     Source Type: Journal    
DOI: 10.2807/1560-7917.es2014.19.27.20850     Document Type: Editorial

References (33)

1. Perez-Sautu U, Pozo F, Cuesta I, Monzon S, Calderon A, Gonzalez M, et al. Y155H amino acid substitution in influenza A(H1N1)pdm09 viruses does not confer a phenotype of reduced susceptibility to neuraminidase inhibitors. Euro Surveill. 2014;19(27):pii=20849.
2. Andrews N, McMenamin J, Durnall H, Ellis J, Lackenby A, Robertson C, et al. Effectiveness of trivalent seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2012/13 end of season results. Euro Surveill. 2014;19(27):pii=20851.
3. Krumholz HM. Neuraminidase inhibitors for influenza. BMJ. 2014; 348:g2548. http://dx.doi.org/10.1136/bmj.g2548.
4. Monto AS, Koopman JS, Longini IM, Jr. Tecumseh study of illness. XIII. Influenza infection and disease, 1976-1981. Am J Epidemiol. 1985;121(6):811-22.
5. Hayward AC, Fragaszy EB, Bermingham A, Wang L, Copas A, Edmunds WJ, et al. Comparative community burden and severity of seasonal and pandemic influenza: results of the Flu Watch cohort study. Lancet Respir Med. 2014;2(6):445-54. http://dx.doi.org/10.1016/S2213-2600(14)70034-7.
6. Thursky K, Cordova SP, Smith D, Kelly H. Working towards a simple case definition for influenza surveillance. J Clin Virol. 2003;27(2):170-9. http://dx.doi.org/10.1016/S1386-6532(02)00172-5.
7. Call SA, Vollenweider MA, Hornung CA, Simel DL, McKinney WP. Does this patient have influenza? JAMA. 2005;293(8):987-97. http://dx.doi.org/10.1001/jama.293.8.987.
8. Lau LL, Nishiura H, Kelly H, Ip DK, Leung GM, Cowling BJ. Household transmission of 2009 pandemic influenza A (H1N1): a systematic review and meta-analysis. Epidemiology. 2012;23(4):531-42. http://dx.doi.org/10.1097/EDE.0b013e31825588b8.
9. Wu JT, Ma ES, Lee CK, Chu DK, Ho PL, Shen AL, et al. The infection attack rate and severity of 2009 pandemic H1N1 influenza in Hong Kong. Clin Infect Dis. 2010;51(10):1184-91. http://dx.doi.org/10.1086/656740.
10. Uyeki TM. Preventing and controlling influenza with available interventions. N Engl J Med. 2014;370(9):789- 91. http://dx.doi.org/10.1056/NEJMp1400034.
11. Kostova D, Reed C, Finelli L, Cheng PY, Gargiullo PM, Shay DK, et al. Influenza Illness and Hospitalizations Averted by Influenza Vaccination in the United States, 2005-2011. PLoS One. 2013;8(6):e66312. http://dx.doi.org/10.1371/journal.pone.0066312.
12. Campbell CN, Mytton OT, McLean EM, Rutter PD, Pebody RG, Sachedina N, et al. Hospitalization in two waves of pandemic influenza A(H1N1) in England. Epidemiol Infect. 2011;139(10):1560-9. http://dx.doi.org/10.1017/S0950268810002657.
13. Louie JK, Acosta M, Winter K, Jean C, Gavali S, Schechter R, et al. Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in California. JAMA. 2009;302(17):1896-902. http://dx.doi.org/10.1001/jama.2009.1583.
14. Bagdure D, Curtis DJ, Dobyns E, Glode MP, Dominguez SR. Hospitalized children with 2009 pandemic influenza A (H1N1): comparison to seasonal influenza and risk factors for admission to the ICU. PLoS One. 2010;5(12):e15173. http://dx.doi.org/10.1371/journal.pone.0015173.
15. Myles PR, Semple MG, Lim WS, Openshaw PJ, Gadd EM, Read RC, et al. Predictors of clinical outcome in a national hospitalised cohort across both waves of the influenza A/H1N1 pandemic 2009-2010 in the UK. Thorax. 2012;67(8):709-17. http://dx.doi.org/10.1136/thoraxjnl-2011-200266.
16. Jefferson T, Jones MA, Doshi P, Del Mar CB, Hama R, Thompson MJ, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev. 2014;4:CD008965.
17. Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12(1):36-44. http://dx.doi.org/10.1016/S1473-3099(11)70295-X.
18. Foppa IM, Haber M, Ferdinands JM, Shay DK. The case test-negative design for studies of the effectiveness of influenza vaccine. Vaccine. 2013;31(30):3104-9. http://dx.doi.org/10.1016/j.vaccine.2013.04.026.
19. Skowronski DM, Janjua NZ, De Serres G, Sabaiduc S, Eshaghi A, Dickinson JA, et al. Low 2012-13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses. PLoS One. 2014;9(3):e92153. http://dx.doi.org/10.1371/journal.pone.0092153.
20. Sullivan SG, Komadina N, Grant K, Jelley L, Papadakis G, Kelly H. Influenza vaccine effectiveness during the 2012 influenza season in Victoria, Australia: influences of waning immunity and vaccine match. J Med Virol. 2014;86(6):1017-25. http://dx.doi.org/10.1002/jmv.23847.
21. Valenciano M, Kissling E, I-MOVE case–control study team. Early estimates of seasonal influenza vaccine effectiveness in Europe: results from the I-MOVE multicentre case-control study, 2012/13. Euro Surveill. 2013;18(7):pii=20400.
22. Puig-Barbera J, Arnedo-Pena A, Pardo-Serrano F, Tirado-Balaguer MD, Pérez-Vilar S, Silvestre-Silvestre E, et al. Effectiveness of seasonal 2008-2009, 2009-2010 and pandemic vaccines, to prevent influenza hospitalizations during the autumn 2009 influenza pandemic wave in Castellon, Spain. A test-negative, hospital-based, case-control study. Vaccine. 2010;28(47):7460-7. http://dx.doi.org/10.1016/j.vaccine.2010.09.042.
23. Talbot HK, Griffin MR, Chen Q, Zhu Y, Williams JV, Edwards KM. Effectiveness of seasonal vaccine in preventing confirmed influenza-associated hospitalizations in community dwelling older adults. J Infect Dis. 2011;203(4):500-8. http://dx.doi.org/10.1093/infdis/jiq076.
24. Kwong JC, Campitelli MA, Gubbay JB, Peci A, Winter AL, Olsha R, et al. Vaccine effectiveness against laboratory-confirmed influenza hospitalizations among elderly adults during the 2010-2011 season. Clin Infect Dis. 2013;57(6):820-7. http://dx.doi.org/10.1093/cid/cit404.
25. Castilla J, Godoy P, Domínguez A, Martínez-Baz I, Astray J, Martín V, et al. Influenza vaccine effectiveness in preventing outpatient, inpatient, and severe cases of laboratory-confirmed influenza. Clin Infect Dis. 2013;57(2):167-75. http://dx.doi.org/10.1093/cid/cit194.
26. Kelly H., Sullivan SG, Grant KA, Fielding JE. Moderate influenza vaccine effectiveness with variable effectiveness by match between circulating and vaccine strains in Australian adults aged 20-64 years, 2007-2011. Influenza Other Respir Viruses. 2013;7(5):729-37. http://dx.doi.org/10.1111/irv.12018.
27. Ohmit SE, Petrie JG, Malosh RE, Cowling BJ, Thompson MG, Shay DK, et al. Influenza vaccine effectiveness in the community and the household. Clin Infect Dis. 2013;56(10):1363-9. http://dx.doi.org/10.1093/cid/cit060.
28. Freemantle N, Shallcross LJ, Kyte D, Rader T, Calvert MJ. Oseltamivir: the real world data. BMJ. 2014;348:g2371. http://dx.doi.org/10.1136/bmj.g2371.
29. Fiore AE, Fry A, Shay D, Gubareva L, Bresee JS, Uyeki TM, et al. Antiviral agents for the treatment and chemoprophylaxis of influenza --- recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2011;60(1):1-24.
30. World Health Organization (WHO). WHO Guidelines for Pharmacological Management of Pandemic Influenza A(H1N1) 2009 and Other Influenza Viruses. Geneva: WHO; 2010. Available from: http://www.who.int/csr/resources/publications/swineflu/h1n1_use_antivirals_20090820/en/.
31. Public Health England (PHE). PHE guidance on use of antiviral agents for the treatment and prophylaxis of influenza. Version 4.1. London: PHE; 2014. Available from: http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1317140666783.
32. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med. 2007;4(10):e296. http://dx.doi.org/10.1371/journal.pmed.0040296.
33. Doshi P. Influenza vaccines: time for a rethink. JAMA Intern Med. 2013;173(11):1014-6. http://dx.doi.org/10.1001/jamainternmed.2013.490.